Get started
Work

82EMF Andexanet Alfa Increases Thrombotic Events Versus 4F-PCC for fXa Inhibitor-Related Intracranial Hemorrhage in Veterans

Year: 2025
Type: article
Study design: Observational Study
Abstract: Two hemostatic agents are commonly used to reverse factor Xa (fXa) inhibitor-related intracerebral hemorrhage (ICH): andexanet alfa (AA) or 4-factor prothrombin complex concentrate (4F-PCC). The optimal reversal strategy is widely debated, and prescribing patterns are unknown. We sought to address a critical need for real-world data in Veterans diagnosed with fXa inhibitor-related ICH by comparing short-term mortality and thrombotic events in patients who received AA vs 4F-PCC.
DOI: 10.1016/j.annemergmed.2025.06.093
Authors: M. Rech, E. Budde, C. Evans, D. Finch, Y. Xia, Z. Huo, J. Han
Language: English
Subfield: Neurology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $3,850
OpenAlex ID: W4413433308
FWCI:
Cites:
Cited by:
Related to: 10